Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of anticoagulation in the treatment of non-occlusive portal vein thrombosis in patients with liver cirrhosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Air Force Military Medical University, China; Fourth Military Medical University
• Treatments: Calcium; Calcium, Dietary; Nadroparin; Warfarin

Criteria

Inclusion Criteria:

• Informed consent was obtained

• liver cirrhosis

• Non-occlusive portal vein thrombosis

• No history of variceal bleeding or receive endoscopy or β-blocker for the prevention of patients with G3 or G2 with red marks within 3 months before enrollment

• No plan for liver transplantation

• Age between 18 and 70

• Child-Pugh score ≤ 11

Exclusion Criteria:

• Acute PVT

• Fibrotic cord of PV

• Isolated splenic vein thrombosis or isolated superior mesenteric vein thrombosis

• Extensive superior mesenteric vein thrombosis involving the distal part

• Known coagulation disorder besides liver cirrhosis

• HCC or other malignant tumor

• Patients with G2 varices with red mark or G3 but did not underwent any preventive endoscopy or β-blockers

• Platelet count < 10×109/L

• Receive contraceptive, anticoagulation or antiplatelet drug

• Receiving thrombolysis treatment

• Receiving TIPS or shunting surgery

• Bleeding tendency

• Recent gastrointestinal bleeding like digestive ulcer or hemorrhagic stroke

• Severe portal hypertension，for example, refractory ascite or acute variceal bleeidng

• Spontaneous bacterial peritonitis

• Severe cardiovascular disorder, endocrine disorder, or mental disease

• Major surgery within 6 months

• History of organ transplantation

• Pregnancy or breast-feeding

• History of HIV

• Poor compliance